Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2018 | Opinion on MRD in CLL: routine use or clinical trials?

Kanti Rai • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia

Measurable residual disease (MRD) is moving into the clinical setting, attracting varying opinions on the method and setting of its use. Here. Kanti Rai, MD, of the Feinstein Institute of Medical Research, Manhasset, NY, discusses his thoughts on the impact and use of MRD in the chronic lymphocytic leukemia (CLL) space. This interview recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from Kanti Rai

9:35
Treatment-changing advancements in CLL: BTK, BCL-2, CD20 & CAR T-cells
Kanti Rai • 25 Oct 2018
1:37
Progress in CLL diagnosis and treatment
Kanti Rai • 25 Oct 2018
4:27
From one generation to the next: the progression of CLL research
Kanti Rai • 14 Aug 2017
5:14
iwCLL – International Workshop on Chronic Lymphocytic Leukemia
Federico Caligaris-Cappio et al. • 29 Feb 2016

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals